Modern Healthcare June 9, 2017
Shelby Livingston

Paying for certain high-cost drugs based on the patient outcomes they deliver is becoming increasingly necessary in the face of skyrocketing drug costs in the U.S., the CEOs of a health insurance company and a pharmaceutical giant agreed Thursday.

The two industries rarely see eye to eye. Harvard Pilgrim Health Care CEO Eric Schultz and Eli Lilly CEO David Ricks joked Thursday at the 2017 AHIP Institute and Expo in Austin, Texas, that they almost called off their panel discussion for fear of having to sit next to each other. But the two found common ground on value-based agreements.

“We in the health insurance industry have used payment for value, payment for performance, for many years with physicians and hospitals,”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: ACO (Accountable Care), CMS, Health System / Hospital, MACRA, Medicaid, Medicare, Medicare Advantage, Patient / Consumer, Payer, Physician, Primary care, Private Exchange, Provider, Public Exchange, Self-insured, Value Based
Home-Based Care Outlook: 55% of Leaders Name Staffing as Top Challenge, Tech Investment on Rise
How doctors lost their freedom and what it means for health care today
The biggest expenses crushing physician practices
Three ways the Trump administration could reinvest in rural America's future, starting with health care
Using AI to reimagine telehealth with a fair, effective billing model

Share This Article